AR012034A1 - ANALOGO DE FACTOR X, DNA RECOMBINANTE QUE CODIFICA PARA DICHO ANALOGO DE FACTOR X Y SU USO, COMPOSICION QUE CONTIENE ANALOGO DE FACTOR X O UNA PROTEINAPRECURSORA DEL MISMO Y SU USO, PROCEDIMIENTO DE PREPARACION DE UNA COMPOSICION CONTENIENDO ANALOGO DE FACTOR X O ANALOGO DE FACTOR Xa O FACTOR Xa ACT - Google Patents
ANALOGO DE FACTOR X, DNA RECOMBINANTE QUE CODIFICA PARA DICHO ANALOGO DE FACTOR X Y SU USO, COMPOSICION QUE CONTIENE ANALOGO DE FACTOR X O UNA PROTEINAPRECURSORA DEL MISMO Y SU USO, PROCEDIMIENTO DE PREPARACION DE UNA COMPOSICION CONTENIENDO ANALOGO DE FACTOR X O ANALOGO DE FACTOR Xa O FACTOR Xa ACTInfo
- Publication number
- AR012034A1 AR012034A1 ARP980100832A ARP980100832A AR012034A1 AR 012034 A1 AR012034 A1 AR 012034A1 AR P980100832 A ARP980100832 A AR P980100832A AR P980100832 A ARP980100832 A AR P980100832A AR 012034 A1 AR012034 A1 AR 012034A1
- Authority
- AR
- Argentina
- Prior art keywords
- analog
- factor
- composition containing
- recombinant dna
- proteinaprecursora
- Prior art date
Links
- 108020004511 Recombinant DNA Proteins 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 108010014173 Factor X Proteins 0.000 abstract 5
- 238000012986 modification Methods 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un análogo de Factor X tiene una modificacion en la region del sitio de corte de activacion de Factor Xa natural, representando dicha modificacion unsitio de procesamiento de una proteasa que no corta naturalmente en esta region de la secuencia de Factor X. Composicion que contiene los anágologs de Factor Xsegun la presente invencion y procedimientos para su preparacion. Un DNA recombinante codificante para este análogo de Factor X está contenido en unvector para expresion recombiannte de la proteína codificada. Un composicion que contenga dicho análogo de Factor X con la modificacion en la region delsitio de corte de activacion. Un procedimiento de preparacion de esta combinacion comprende proveer un ácido nucleico,transforamr una célulaadecuada, expresar el análogo de Factor X y aislar y purificarlo. La composicion y/o el DNA recombinante se usan en la preparacion de un agentefarmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0033597A AT405516B (de) | 1997-02-27 | 1997-02-27 | Faktor x-analoge mit modifizierter proteasespaltstelle |
Publications (1)
Publication Number | Publication Date |
---|---|
AR012034A1 true AR012034A1 (es) | 2000-09-27 |
Family
ID=3487868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980100832A AR012034A1 (es) | 1997-02-27 | 1998-02-25 | ANALOGO DE FACTOR X, DNA RECOMBINANTE QUE CODIFICA PARA DICHO ANALOGO DE FACTOR X Y SU USO, COMPOSICION QUE CONTIENE ANALOGO DE FACTOR X O UNA PROTEINAPRECURSORA DEL MISMO Y SU USO, PROCEDIMIENTO DE PREPARACION DE UNA COMPOSICION CONTENIENDO ANALOGO DE FACTOR X O ANALOGO DE FACTOR Xa O FACTOR Xa ACT |
Country Status (17)
Country | Link |
---|---|
US (2) | US6573071B1 (es) |
EP (1) | EP0966536B1 (es) |
JP (1) | JP4317976B2 (es) |
AR (1) | AR012034A1 (es) |
AT (2) | AT405516B (es) |
AU (1) | AU744428B2 (es) |
BR (1) | BR9807627A (es) |
CA (1) | CA2282707A1 (es) |
CZ (1) | CZ298298B6 (es) |
DE (1) | DE59813518D1 (es) |
ES (1) | ES2263199T3 (es) |
HU (1) | HU225246B1 (es) |
IL (2) | IL131346A0 (es) |
NO (1) | NO327878B1 (es) |
PL (1) | PL190734B1 (es) |
SK (1) | SK286359B6 (es) |
WO (1) | WO1998038317A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT405517B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
IL129427A0 (en) * | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
AT410216B (de) * | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
AU2001249389A1 (en) * | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
US7223577B2 (en) * | 2000-11-17 | 2007-05-29 | Allergan, Inc. | Post-translational modifications and Clostridial neurotoxins |
FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
FR2841904B1 (fr) * | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
WO2004033630A2 (en) * | 2002-10-04 | 2004-04-22 | Schering Aktiengesellschaft | Modified hepsin molecules having a substitute activation sequence and uses thereof |
CA2592521A1 (en) * | 2004-08-17 | 2006-02-23 | Csl Behring Gmbh | Modified vitamin k dependent polypeptides |
EP1728798A1 (en) * | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
EP1820508A1 (en) * | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
ATE548380T1 (de) | 2006-04-20 | 2012-03-15 | Kringle Pharma Inc | Mutante des hgf-precursor-proteins und aktivierte form davon |
GB0710321D0 (en) * | 2007-05-30 | 2007-07-11 | Nhs Blood & Transplant | Method |
US9956272B2 (en) | 2007-05-30 | 2018-05-01 | Bio Products Laboratory Limited | Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same |
EP2185701A4 (en) * | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
LT3078743T (lt) | 2007-09-28 | 2020-09-25 | Portola Pharmaceuticals, Inc. | Antikūnai xa veiksnio inhibitoriams ir jų naudojimo būdai |
JP5709316B2 (ja) * | 2008-11-14 | 2015-04-30 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法 |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
EA020843B1 (ru) | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
EP2414517B1 (en) | 2009-03-30 | 2016-09-21 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
ES2705249T3 (es) | 2009-06-08 | 2019-03-22 | Amunix Operating Inc | Polipéptidos reguladores de glucosa y métodos para su producción y uso |
CA2767858C (en) | 2009-07-15 | 2019-02-12 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
CA2772051C (en) * | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
WO2013049804A1 (en) * | 2011-09-30 | 2013-04-04 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
EP3549953A1 (en) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
EP2814840B1 (en) | 2012-02-15 | 2019-11-13 | Bioverativ Therapeutics Inc. | Factor viii compositions and methods of making and using same |
EP2819788B1 (en) | 2012-02-27 | 2018-08-22 | Amunix Operating Inc. | Xten conjugate compositions and methods of making same |
GB201211617D0 (en) | 2012-06-29 | 2012-08-15 | Univ Aberdeen | Production of cyclic peptides |
WO2014018120A1 (en) | 2012-07-25 | 2014-01-30 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
US20150343034A1 (en) | 2013-01-31 | 2015-12-03 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
FR3001729B1 (fr) * | 2013-02-04 | 2015-03-06 | Lab Francais Du Fractionnement | Mutants du facteur x |
CN105008530A (zh) * | 2013-03-12 | 2015-10-28 | 诺和诺德股份有限公司 | 凝血酶敏感性凝固因子x分子 |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
MY173548A (en) | 2013-09-24 | 2020-02-04 | Pfizer | Fxa variant compositions |
RU2585532C2 (ru) * | 2014-01-31 | 2016-05-27 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук"(ФИЦ Биотехнологии РАН) | Плазмида для экспрессии рекомбинантного фактора свёртываемости крови ix человека, клетка сно - продуцент рекомбинантного фактора свёртываемости крови ix человека и способ получения указанного фактора |
US10676731B2 (en) | 2014-08-19 | 2020-06-09 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor IX function |
WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
EP3341009A4 (en) | 2015-08-28 | 2019-05-01 | Amunix Pharmaceuticals, Inc. | CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF PREPARING AND USING THE SAME |
TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療a型血友病的方法 |
KR102613936B1 (ko) * | 2020-11-13 | 2023-12-15 | 한국생명공학연구원 | 자가분해능이 저하된 켁신 효소 및 이의 생산 방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT366916B (de) | 1980-04-02 | 1982-05-25 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes auf basis von menschlichen oder tierischenproteinen |
US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
AT382783B (de) | 1985-06-20 | 1987-04-10 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes |
US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
ES2109336T3 (es) | 1990-11-26 | 1998-01-16 | Genetics Inst | Expresion de pace en celulas huesped y metodos de utilizacion de la misma. |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
DE4325872C1 (de) | 1993-08-02 | 1994-08-04 | Immuno Ag | Virusinaktivierte Faktor Xa-Präparation |
AT401270B (de) | 1994-09-26 | 1996-07-25 | Immuno Ag | Verfahren zur quantifizierung von genomischer dna |
AT404838B (de) | 1995-11-24 | 1999-03-25 | Immuno Ag | Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen |
AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
-
1997
- 1997-02-27 AT AT0033597A patent/AT405516B/de not_active IP Right Cessation
-
1998
- 1998-02-25 AR ARP980100832A patent/AR012034A1/es not_active Application Discontinuation
- 1998-02-27 EP EP98903943A patent/EP0966536B1/de not_active Expired - Lifetime
- 1998-02-27 SK SK1171-99A patent/SK286359B6/sk not_active IP Right Cessation
- 1998-02-27 PL PL98335382A patent/PL190734B1/pl not_active IP Right Cessation
- 1998-02-27 ES ES98903943T patent/ES2263199T3/es not_active Expired - Lifetime
- 1998-02-27 HU HU0100652A patent/HU225246B1/hu not_active IP Right Cessation
- 1998-02-27 BR BR9807627-2A patent/BR9807627A/pt not_active IP Right Cessation
- 1998-02-27 JP JP53706298A patent/JP4317976B2/ja not_active Expired - Lifetime
- 1998-02-27 IL IL13134698A patent/IL131346A0/xx active IP Right Grant
- 1998-02-27 US US09/367,791 patent/US6573071B1/en not_active Expired - Lifetime
- 1998-02-27 CZ CZ0303299A patent/CZ298298B6/cs not_active IP Right Cessation
- 1998-02-27 CA CA002282707A patent/CA2282707A1/en not_active Abandoned
- 1998-02-27 DE DE59813518T patent/DE59813518D1/de not_active Expired - Lifetime
- 1998-02-27 AT AT98903943T patent/ATE324454T1/de active
- 1998-02-27 WO PCT/AT1998/000045 patent/WO1998038317A1/de active IP Right Grant
- 1998-02-27 AU AU62002/98A patent/AU744428B2/en not_active Ceased
-
1999
- 1999-08-10 IL IL131346A patent/IL131346A/en not_active IP Right Cessation
- 1999-08-26 NO NO19994139A patent/NO327878B1/no not_active IP Right Cessation
-
2003
- 2003-04-04 US US10/407,123 patent/US7220569B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6573071B1 (en) | 2003-06-03 |
NO994139D0 (no) | 1999-08-26 |
PL190734B1 (pl) | 2005-12-30 |
IL131346A0 (en) | 2001-01-28 |
HU225246B1 (en) | 2006-08-28 |
AU744428B2 (en) | 2002-02-21 |
BR9807627A (pt) | 2000-02-22 |
EP0966536A1 (de) | 1999-12-29 |
CA2282707A1 (en) | 1998-09-03 |
AT405516B (de) | 1999-09-27 |
DE59813518D1 (de) | 2006-06-01 |
ATA33597A (de) | 1999-01-15 |
NO994139L (no) | 1999-10-27 |
EP0966536B1 (de) | 2006-04-26 |
US7220569B2 (en) | 2007-05-22 |
ES2263199T3 (es) | 2006-12-01 |
NO327878B1 (no) | 2009-10-12 |
AU6200298A (en) | 1998-09-18 |
CZ303299A3 (cs) | 2000-02-16 |
PL335382A1 (en) | 2000-04-25 |
CZ298298B6 (cs) | 2007-08-22 |
IL131346A (en) | 2007-05-15 |
JP4317976B2 (ja) | 2009-08-19 |
ATE324454T1 (de) | 2006-05-15 |
HUP0100652A3 (en) | 2003-01-28 |
HUP0100652A1 (hu) | 2001-06-28 |
WO1998038317A1 (de) | 1998-09-03 |
JP2001513631A (ja) | 2001-09-04 |
US20030181381A1 (en) | 2003-09-25 |
SK286359B6 (sk) | 2008-08-05 |
SK117199A3 (en) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR012034A1 (es) | ANALOGO DE FACTOR X, DNA RECOMBINANTE QUE CODIFICA PARA DICHO ANALOGO DE FACTOR X Y SU USO, COMPOSICION QUE CONTIENE ANALOGO DE FACTOR X O UNA PROTEINAPRECURSORA DEL MISMO Y SU USO, PROCEDIMIENTO DE PREPARACION DE UNA COMPOSICION CONTENIENDO ANALOGO DE FACTOR X O ANALOGO DE FACTOR Xa O FACTOR Xa ACT | |
AR009436A1 (es) | UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS. | |
EP0776331A4 (en) | HIGHER ORDER STRUCTURE AND BINDING OF PEPTIDE NUCLEIC ACIDS | |
ATE273320T1 (de) | Fusogene liposomen | |
BR9915542A (pt) | Conjugados de polìmero de interferon beta-1a e usos | |
RU95115239A (ru) | Аналог эритропоэтина | |
AR008727A1 (es) | COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO | |
BRPI0109494B8 (pt) | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii | |
GB2338237A (en) | In vitro peptide or protein expression library | |
AR077576A2 (es) | Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos | |
FI953378A0 (fi) | Sytokiiniä pidättävät aineet | |
MX9207334A (es) | Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene | |
NO20052216L (no) | Smertestillende midler | |
ES2054612T3 (es) | Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas. | |
HK1066551A1 (en) | Tolerogenic peptides from myelin basic protein | |
AR012499A1 (es) | Una secuencia quimerica de acido nucleico que codifica una proteina de fusion, un vector de expresion que comprende dicha secuencia quimerica, una celula huesped transformada que contiene dicho vector, la proteina de fusion obtenida y un metodo in vitro para la preparacion de un polipeptido recombin | |
NO930428L (no) | Proteinstrukturen til plantetoksingelonin | |
HUP0001458A2 (hu) | Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása | |
ES2078925T3 (es) | Proteinas de la estreptoquinasa, genes correspondientes, recombinantes plasmidicos correspondientes, transformantes correspondientes y procedimientos para su preparacion. | |
PT1007717E (pt) | Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta | |
DE69504795D1 (de) | Methoden zur synthese und reinigung von peptiden | |
AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry | |
DK312787D0 (da) | Polypeptider, fremgangsmaade til deres fremstilling, dna som koder for polypeptiderne, vektorer indeholdende saadanne gensekvenser og laegemidler indeholdende polypeptiderne | |
AR065908A2 (es) | Una composicion inmunogenica que comprende un polipeptido quimerico codificado por una molecula portadora que contiene una secuencia polinucleotidica que codifica en parte una glicoproteina de lyssavirus, polipeptidos, la molecula portadora, un metodo para la preparacion in vitro o in vivo de unpoli | |
AR012744A1 (es) | Molecula de acido nucleico que codifica una proteina vinculadora de sucrosa, proteina vinculadora de sucrosa y metodo para producir una proteinavinculadora de sucrosa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |